November 28, 2014 11:16 PM ET

Biotechnology

Company Overview of Microbiotix, Inc.

Company Overview

Microbiotix, Inc., a biopharmaceutical company, engages in the research and development of small molecule anti-infective drugs for the treatment of infectious diseases. Its products include MBX-700 and MBX-701 that are irreversible non-nucleoside inhibitors of the hepatitis C virus polymerase; and MBX-400, a potent nucleoside DNA polymerase inhibitor for the treatment of human cytomegalovirus. The company also engages in the clinical research and development of antibacterial and antiviral discovery programs in the areas of filovirus, malaria, gram-negative bacterial infections, multi-drug resistant tuberculosis, and influenza. It serves its customers worldwide. Microbiotix was founded in 199...

One Innovation Drive

Worcester, MA 01605

United States

Founded in 1998

Phone:

508-757-2800

Fax:

508-757-1999

Key Executives for Microbiotix, Inc.

Chief Executive Officer
Chief Operating Officer and Director
Age: 46
Director of Chemistry
Chief Scientific Officer
Consultant and Member of The Scientific Advisory Board
Compensation as of Fiscal Year 2014.

Microbiotix, Inc. Key Developments

Microbiotix, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013

Microbiotix, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 . Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

Microbiotix, Inc. and Merck & Co. Inc. Announce Exclusive Worldwide Licensing Agreement for HCV NS5B Non-Nucleoside Polymerase Inhibitors

Microbiotix, Inc. entered into an exclusive licensing agreement with Merck & Co. Inc. As part of this agreement, Microbiotix gains worldwide rights to develop, manufacture and commercialize MBX-700 and MBX-701 (formerly SCH 900942 and SCH 900188), two non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. MBX-700 is in Phase I clinical testing and MBX-701 is currently in preclinical development. Merck is eligible for milestone payments during development stages of the candidates, and for royalty payments from any resulting products. Specific terms of the agreement were not disclosed.

Microbiotix, Inc. Presents at BIO Asia International Conference 2013, Jan-29-2013

Microbiotix, Inc. Presents at BIO Asia International Conference 2013, Jan-29-2013 . Venue: Grand Hyatt Tokyo, 6-10-3 Roppongi, Minato-Ku, Tokyo 106-0032, Japan.

Similar Private Companies By Industry

Company Name Region
AlphaGenix, Inc. United States
Millennium Life Sciences, Inc. United States
Predictive Biomarker Sciences, Inc. United States
Genetic Chemistry Inc. United States
GeneCentric Diagnostics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Microbiotix, Inc., please visit www.microbiotix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.